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Nevertheless, further studies investigating the 
mechanisms of C5a and its receptor in canine 
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ABSTRACT
A study of the development of spontaneous tumours in dogs gives many benefits in oncology research 
due to the similarity between dog and human cancer in terms of epidemiologic, biologic and clinical 
features. There is evidence that the complement component 5 anaphylatoxin (C5a) and its receptor are 
involved in the development of many types of tumour due to its inflammatory properties. The purpose 
of this study was to determine the expression of C5a on several types of canine spontaneous tumour 
i.e. mammary tumour, lung tumour, testicular tumour and melanoma. The expression of C5a in these 
tumours was compared with normal tissue from the breasts, lungs, testes and skin. The total of eight 
post-mortem canine tissues were collected from University Veterinary Hospital (UVH), University 
Putra Malaysia and stored in a preservative solution (RNAlater) to keep the RNA from degrading. The 
RNA was extracted using the Qiagen RNA Extraction Kit and a cDNA synthesis was carried out using 
a one-step PCR kit (Promega, USA). The expression of C5a was determined using reverse transcriptase 
PCR (RT-PCR) and Quantitative real-time PCR (qPCR) techniques. The results showed that all types 
of tumour gave higher expression of C5a compared to normal tissue. This means that the CT value for 
the tumours was below 30 cycles except for melanoma and the expression of C5a of normal tissues was 
above 30 cycles. This finding suggests that C5a and its receptor may be involved in the development 
of tumours in dogs and can be used as a tumour biomarker for both animals and humans in the future. 
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INTRODUCTION
The choice of dogs as the animal model to study the role of the complementary protein C5a 
in the development of spontaneous tumours justifies its role as a good and reliable tool to gain 
further knowledge about spontaneous tumours and potential remedies. Dogs with spontaneous 
tumours may be used as good animal models based on several characteristics that have been 
studied by previous researchers (Rowell et al., 2011; Pinho et al., 2012). These similarities 
between canine and human tumours have been known to be related to genetics, treatment targets 
and physiology (Khanna et al., 2006; Breen & Modiano, 2008; Paoloni & Khanna, 2008).
C5a is one of the proteins in the immune system that is involved in the inflammation 
reaction resulting in recruiting inflammatory cells to targeted regions in the body. Previous 
studies found that C5a was involved in many types of disease related to inflammation reaction 
(Dondorp et al., 2005) and cancers (Kim et al., 2005; Markiewski et al., 2008; Hezmee et al., 
2011). However, the exact role of C5a in the body is still unclear due to lack of research and 
information about this complement.
Complement proteins, particularly of C5a, have been always thought to be one of the most 
vital substances in the host defence mechanisms. Nonetheless, many studies recently have 
implicated the role of complement activation in the development of multiple inflammatory 
and immunological diseases, including sepsis (Ward, 2004), acute respiratory distress 
syndrome (Robbins et al., 1987), glomerulonephritis (Welch, 2002), ischemia-reperfusion 
injury (Arumugam et al., 2004a), rheumatoid arthritis (Linton & Morgan, 1999) and asthma 
(Hawlisch et al., 2004).
C5a receptors (C5aR) can be located on the myeloid cells such as the phagocytic leukocytes 
(Chenoweth & Hugli, 1978; Kurimoto et al., 1989; Gerard & Gerard, 1991; Werfel et al., 
1992; Revollo et al., 2005),  as well as those of a non-myeloid origin such as hepatocytes, 
lung vascular smooth muscle cells, bronchial and alveolar epithelial cells (Haviland et al., 
1995; Riedemann et al., 2002), articular chondrocytes (Onuma et al., 2002) and astrocytes 
(Gasque et al., 1995). Previous studies showed that there was a 70-percent similarity of the 
C5a receptor between canines, humans, rats and bovines. Therefore, the canine C5a receptor 
is considered orthologous to the human C5a receptor, and this represents a surprisingly high 
interspecies variability compared with other G-protein-coupled-receptors (Perret et al., 1992). 
There are various functions of this receptor in the cells and tissues. One of the most 
important functions of this receptor is in the development of sepsis. It is achieved by the 
recruitment of neutrophils by C5a/C5aR signalling. C5a/C5aR signalling in neutrophils leads 
to activation of phosphatidylinositol 3-kinases (PI3K)/ a serine/threonine kinase (PI3K/Akt) 
pathways, which provide survival signals for neutrophils. Assembly of NADPH oxidase can 
be triggered by C5a/C5aR signalling, resulting in H2O2 productions in organs and tissues. An 
increased number of neutrophils together with H2O2 generation may be linked to tissue injury 
and multiple organ failure (Guo & Ward, 2005).   
With this discovery, attention is shifted towards the prevention of the excessive complement 
activation that may lead to the development of multiple diseases. Therapeutic research has been 
conducted on laboratory animal models using trial antagonistic and agonist drugs to further 
understand the actions of complement proteins, particularly C5a. Therefore, the objective of 
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this preliminary study is to determine the availability of C5a receptors in the spontaneous 
tumour tissue of dogs. With the vast advancement of anti-complementary drugs available 
commercially, this study will provide a stepping stone for more detailed research into the use 
of these drugs to treat these tumours in dogs and, subsequently, in humans as well.
MATERIALS AND METHOD
Canine Spontaneous Tumours and Sample Preparation
A total of eight samples of different spontaneous canine tumours and normal tissues were 
obtained from excised tissues of diagnosed cases of canine spontaneous tumours from the 
University Veterinary Hospital (UVH), Faculty of Veterinary Medicine, Universiti Putra 
Malaysia (UPM).  Table 1 shows the types of tumour based on their histopathological findings 
as diagnosed by the veterinary pathologist in Faculty of Veterinary Medicine, Universiti Putra 
Malaysia. A number of normal tissues were also obtained from pathological archives of the post 
mortem unit of Faculty of Veterinary Medicine for comparison. All the tissues were submerged 
in a sterile RNAlater® solution (Ambion, Inc., USA) for PCR analysis and sequencing of C5aR 
expression.
The tissues that were submerged in the RNAlater® solution were treated for conversion 
to PCR products. The tissues were finely chopped into pieces of size 1-mm in diameter (50-
100mg) and then transferred into a tube containing TRIZOL® solution (Invitrogen™, USA) 
for preparation of PCR products.
RNA Isolation and cDNA Synthesis 
The tissues in the TRIZOL® were homogenised using scalpel blade into much smaller pieces and 
vortexed vigorously. The digested tissues were left at 25 ºC for 5 min. The insoluble materials 
were removed by centrifuge to obtain solutions containing the digested tissues at 13,000 rpm 
for 10 min at 4 ºC.  The supernatants were transferred into a new tube. Chloroform was then 
added to the supernatants and the tubes were shaken vigorously and left at 25 ºC for 5 min and 
centrifuged at 13,000 rpm for 10 min at 4 ºC. The clear supernatant was transferred to a fresh 
tube containing isopropanol solution. The solutions were left at 25 ºC for 10 min and were 
centrifuged at 13,000 rpm for 15 min at 4 ºC. The supernatants were discarded. The pelleted 
RNAs were washed with a 75% ethanol solution and the solutions were centrifuged at 9,000 rpm 
for 5 min at 4 ºC. The RNA in the tubes was left to dry for 5 min. The process was continued 
with the RNA extractions. The pellets containing RNA products were re-suspended with 
nuclease-free water and heated at 55 ºC for 15 min. DNAse1 (Invitrogen™, USA) treatment 
TABLE 1 : Types of Tumour Obtained
Lung carcinoma
Mammary carcinoma
Melanoma 
Testicular tumour 
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was conducted to remove traces of contaminating DNA. For the final preparation of the RNA 
extraction, cDNA syntheses of the RNA-treated cells were performed using the Universal 
RiboClone® cDNA synthesis system (Promega Corporation, USA). The RNAs from tumour 
tissues were used for C5a receptor detection and expression using a PCR machine.
Cloning and Sequence Analysis of Canine C5aR (CD88)
The primers for this study were designed according to the study by Perret et al. (1992). The 
C5aR cloning sequences and Hypoxanthine phosphoribosyltransferase (HPRT) genea used in 
this study were as follows:
C5aF = 5’ GCT CAT CCT GCT CAA CAT GTA C 3’
C5aR = 5’ CCG CGG AAG ATG AAC GA 3’
HPRTF = 5’ TGC TCG AGA TGT GAT GAA GG 3’
HPRTR = 5’ TCC CCT GTT GAC TGG TCA TT 3’
The primer sequences were obtained from BASE Life Sciences Holdings (Singapore). The 
primers were aliquot into smaller tubes and the leftover aliquot were stored in -80ºC. One vial 
of each primer was used for this assay. Routine thermal reaction work out was conducted on 
the cDNA aliquots of 4µg of mammary tumour samples in 40 cycles in these conditions: pre-
denaturing step for 10 min at 95 ºC, denaturation step for 1 min at 94 ºC, annealing temperature 
of 1 min at 50 ºC, extension step for 1 min at 72 ºC and extension procedure for 10 min at 72 
ºC. Other annealing temperature tested was 55 ºC while HPRT primers were used to serve as 
canine housekeeping genes. Each PCR product from the thermal reaction was then subjected 
to gel electrophoresis through a 1.5% agarose gel and stained with ethidium bromide for 
screening purposes. 
Quantification of Target Gene Expression
The quantification and negative control of C5aR gene transcripts were carried out by real time 
quantitative PCR using the Applied Biosystems (Victoria, Australia) and Sybr Green qPCR 
kit (Promega, USA). The PCR reaction mixture (20 µl) contained 10 µl of Sybr Green qPCR 
mix, 0.5 µl of the above-described primer mix 10 nM each, 1 µl RNAs inhibitor and 2 µl of 
cDNA template. The PCR protocol was: UNG enzyme incubation at 45 °C for 45 min; initial 
denaturation at 94 °C for 5 min; 40 cycles for primer annealing, 60 °C for 30 s for primer 
extension and an elevated temperature of 72 °C for 30 s for fluorescent data acquisition; and a 
final extension step at 80 °C for 2 s to allow the formation of fully duplexed DNA. To check 
the specificity of the amplified products, a melting curve analysis was performed immediately 
following the completion of the PCR. The melting protocol consisted of heating from 65 to 
95 °C at a rate of 0.2 °C per step, and each step was held for 1 s for data acquisition. For each 
sample analysed, the mean Ct value based on the results of all experiments was calculated, 
together with that of the corresponding standard samples. The canine C5aR cDNA copy numbers 
were then normalised using the calculated HPRT cDNA copy numbers (the mean) of the same 
sample and run. This number was obtained by applying the respective Ct values for HPRT in 
the standard dilution curve of the same dilution.
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RESULTS AND DISCUSSION
The study of complement 5a (C5a) is a new field of study in Malaysia. It is important to study 
C5a due to lack of information regarding the exact role of C5a in the body and the involvement 
of this protein in various diseases. Many studies have shown that C5a is involved in many 
pathological states related to inflammatory disease and cancer (Dondorp et al., 2005; Fitzpatrick, 
2001; Hong et al., 2010). The expression of C5a and its receptor can be defined using the 
reverse transcriptase Polymerase Chain Reaction (rt-PCR) and real time PCR (qPCR). These 
techniques are  suitable for use in detecting the expression of C5a biology due to its properties, 
which are inexpensive, rapid response and high sensitivity in producing millions of copies of 
DNA even though the quality of the DNA may be poor (Erlich, 1989).
Expression of C5a Receptor Protein in Canine Tumours
Fig.1 (A) shows the band for the housekeeping gene i.e. the HPRT gene. Meanwhile, Fig.1 
(B) shows the single bands that were obtained from the C5a primer in tumour tissues in which 
Lane 1 is mammary carcinoma, lane 2 is lung carcinoma, lane 3 is melanoma and lane 4 is 
testicular tumour. The result indicates that C5a was expressed in all types of tumour except 
melanoma tissues while there was none in normal tissue (data not shown). The DNA ladder 
marker (Promega, USA) was used as a reference in which each band contributed to 100 bp size. 
The single band given for the PCR products showed that the polymerisation of C5aR 
using specific C5aR primers had occurred in the tissues. This result is a positive indicator for 
determining the role of the C5a and its receptor in the development of spontaneous cancer. It 
is due to the presence of PCR products in most of the tumour tissues; PCR products are absent 
in normal tissues. The presence of PCR products indicates that there was an abundance of 
C5a receptors in the tissues. This finding was consistent with previous studies that showed 
the involvement of C5a in many pathological states especially cancer (Smedegård et al., 
1989; Czermak et al., 1999; Huber-Lang et al., 2001; Huber-Lang et al., 2006; Markiewski, 
2008; Patel et al., 2008). RT-PCR is the most sensitive procedure to detect RNA because it 
can detect and amplify much smaller samples (Kim & Kim, 2003) and also from a single cell. 
Housekeeping genes or internal control genes are normally used as a reference for the genes 
of interest (Suzuki et al., 2000). It is constant in certain cell types but varies in other types of 
cell or tissue (Thellin et al., 1999; Warrington et al., 2000). Thus, the use of housekeeping 
genes is important in gene expression analysis.
                      Ladder    1         2         3        4                              4         3         2        1     Ladder
            A)       B) 
500 bp 500 bp
Fig.1: The expression of C5a receptor via Reverse Transcriptase PCR. Result of electrophoresis in 1.5% 
TBE-agarose gel of RT-PCR product using two sets of primers; A) HPRT primer as a housekeeping gene 
for each tumour tissues and B) C5a Primer with tumour tissues in which lane 1: Mammary carcinoma; lane 
2: Lung carcinoma; lane 3: Melanoma and lane 4: Testicular tumour using 100bp ladder (Promega, USA).
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Determination of cDNA Sequencing of Canine C5aR (CD88)
Nucleotide sequencing of canine C5aR cDNA revealed a coding region of 1357 bp. The 
deduced amino acid sequences of canine C5aR contained 657 residues. Sequencing of these 
digests showed that the recombinant was 97% homologous to the canine C5aR gene sequence 
deposited in GenBank under the accession no. X65860.  The homologies of the cDNA and 
amino acid sequences among some mammalian species were calculated (Table 2).  
At the cDNA sequence level, canine C5aR was found to show high homologies with human 
C5aR (91%) and rats C5aR (92%). This result indicates that the role of C5a in the canine 
cells provided a direct indicator of the development of tumours in humans regarding the high 
sequence homology among them. Although rat models have a higher sequence homology for 
C5aR sequence, in terms of genome sequence, canine models have a higher similarity with 
human (79%) compared to rat (69%) models (Davis et al., 2014). Besides that, the use of 
rats in research cannot always be faithfully extrapolated to human patients. Canines are more 
suitable for use in the study of cancer due to their characteristics of experiencing spontaneous 
disease with high frequency, developing the same types of cancer observed in humans and 
being receptive to the same therapeutic strategies (Pontius et al., 2007). In addition, both 
canines and owners are susceptible to getting the same type of cancer due to exposure to the 
same environmental factors.
The use of dogs as a model of a variety of cancers in human has been suggested due to 
the fact that the characteristics and gene sequence of C5a in canines mimic those in humans 
(Rowell et al., 2011; Pinho et al., 2012). Hence, it is important to study the effects of C5a/
c5aR on the development of tumours in canines. Unfortunately, due to the limited number of 
samples because of difficulty in getting spontaneous tumour samples from veterinary hospital 
in Malaysia, this study was unable to statistically exhibit these arguments on a much bigger 
scale. Nevertheless, this preliminary study provided a good platform for exploring the potential 
of using C5a/C5aR markers in clinical applications for diagnostic tools. It also highlighted 
prognostic indicators and potential targets for therapeutic and preventive strategies and supports 
efforts to evaluate clinical trials on the efficacy of C5a/C5aR-blockers in the treatment of 
canine tumours. 
Quantification of C5aR Gene Expression 
Four types of canine tumour were used in this study i.e. mammary carcinoma, lung carcinoma, 
melanoma and testicular tumour. Each tumour was compared to its normal tissue from the 
particular part of the body. The result showed that the mean CT value for the tumours was 
below 30 cycles except for melanoma and that the expression of C5a of normal tissues was 
TABLE 2: Nucleic Acid and Amino Acid Sequence Homologies of Canine C5aR, Compared with Other 
Mammalian Species
Dog Human Mouse Rats Sheep Pig Cattle
Nucleic acid (%) 91.0 91.0 92.0 85.0 88.0 85.0
Amino acid   (%) 82.0 86.0 85.0 85.0 89.0 85.0
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above 30 cycles. The differentiation of CT value between tumour tissues and normal tissues 
for mammary carcinoma, testicular tumour, lung carcinoma and melanoma were 15, 11, 5 and 
2 cycles, respectively. 
The CT value is a parameter used in detection and quantification of C5a expression in 
canine spontaneous tumours. The CT value form is in indirect proportion to the amount of 
PCR product in a reaction (Higuchi et al., 1993). The higher expression of gene of interest 
gives a lower CT value due to the principle of RT-PCR i.e. the detection of samples depends 
on the fluorescent signal that is captured by computer software where the result is calculated 
based on cycle threshold (CT) value. The higher the starting copy number of the nucleic acid 
target, the sooner a significant increase in fluorescence is observed. The result showed that the 
expression of C5a in canine spontaneous tumours was higher than in normal tissues due to the 
lower CT value of tumour tissues compared to normal issues. 
These findings are supported by the previous study of Hezmee et al. (2011) in which the 
researchers found that the expression of C5a in canine malignant tumours was higher compared 
to that in benign tumours while there was no expression of C5a in canine normal mammary 
tissues. This suggests that C5a may have a direct biological effect on cancer cells. This finding 
is also in agreement with  another study done on C5aR expression in bovine mammary tissues, 
in which C5aR was also expressed by inflammatory cells from bovine mammary tissues, but not 
from normal or inactive cells  (Nemali et al., 2008). Hence, this study suggested that activation 
of C5a receptors may have a consequence in tumour development. However, the use of a small 
sample size in this study means it is not clearly possible to make a proper correlation between 
the expression of C5aR and tumour types. Besides that, many precautionary steps starting from 
preparation protocol to analysing of results need to be emphasised due to the different type of 
tissues that can lead to a false positive result. 
The Real Time Polymerase Chain Reaction (qPCR) is a method that can be used to 
replace the weakness of PCR (Erlich et al., 1989; Whelan et al., 2003). This system provides 
greater sensitivity for amplicon detection compared to conventional PCR that uses gel-based 
detection. It can be seen in the results, where conventional PCR gave a single band to most of 
the tumour tissues but there was no band for melanoma and normal tissues. This was due to 
very low expression of C5a in these tissues. However, when the samples were put through the 
real-time PCR technique, both tumours and normal tissues gave a CT value result. This was 
due to the capability of real-time PCR of detecting DNA up to 50 fg and its higher sensitivity, 
up to tenfold more, than that of conventional PCR. Based on the reverse transcriptase PCR 
and Real Time PCR, the results showed that the expression of C5a was up-regulated in all the 
tumour tissues except melanoma and down-regulated in all normal tissues (Fig.2).
Even though the role of C5aR in the development of canine tumours remains unclear, there 
are studies that suggest a link between chronic inflammatory response and the development 
of cancer (Coussens & Werb, 2002; Tan & Coussens, 2007).  C5a and its receptors play an 
important role in various other disorders involving chronic inflammatory responses (Robbins 
et al., 1987; Welch, 2002; Arumugam et al., 2004a; Hawlisch et al., 2004; Ward, 2004) and 
due to its property of being one of the most potent inflammatory peptides, excessive activation 
of complement proteins towards their receptors in tissues has been hypothesised to lead to the 
progression of tumour cells (Tan & Coussens, 2007).  
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The complex mechanism of humoral immunity of the host, which includes the activation 
of C5a and its receptors in tissue and cell surfaces, is still not fully understood; nevertheless, 
receptors for the Fc portion of IgG (especially FcGRIII) and complement factors (particularly 
C5a/C5aR) are recognised as co-dominant effectors in the process (Schmidt & Gessner, 2005). 
Tissues damaged by autoimmune disorders and by cancer have similar characteristics such as 
in chronic innate immune cell infiltration, tissue re-modelling, angiogenesis, altered survival 
pathways (Sapir & Shoenfeld, 2005). It would seem there is a possibility that the same immune 
complex effector pathways are involved in pathogenesis of both disease (Tan & Coussens, 
2007). Although this study did not provide any data regarding the treatment of these tumours, 
there are, however, scientifically tested and proven anti-complement drugs that are used to 
counter the effects of excessive and chronic C5a/C5aR activation (Short et al., 1999; Arumugam 
et al., 2002; Woodruff et al., 2003; Arumugam et al., 2004b).  
CONCLUSION
This preliminary study found that the expression of C5a was up-regulated in most of the 
spontaneous canine tissues and down-regulated in all normal tissues. This study gave a positive 
indicator of the role of C5a in the development of spontaneous tumours in canines as well as 
in humans due to high homology of the C5a sequence in both dogs and humans. However, 
further study is warranted to fully understand the mechanism of tumour development due to 
action of C5a/C5aR; data for a higher number of tumour-bearing animals and the effects of 
C5a/C5aR antagonist and agonist drugs should be included in such study. 
Fig.2: The magnitude of expression of C5a via Real Time PCR. The CT value recorded for C5a is higher 
in normal tissue compared to the tumour tissue. The CT values recorded is indirectly proportional with 
concentration of C5a in which the higher the concentration of C5a, the lower the CT values recorded. 
The HPRT gene was used as a housekeeping gene to validate the results. The red bars show that the 
tumour tissues started with lane 1: Lung carcinoma; lane 2: Melanoma; lane 3: Testicular tumour; and 
lane 4: Mammary tumour. The green bars show the normal tissues for each type of tumour starting with 
the lung tissue followed with skin, testis and mammary tissues.
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